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Abstract
Virus-specific CD81 T cells are thought to play an important role in resolving acute hepatitis C virus
(HCV) infection as viral clearance has been associated with a strong and sustained CD81 T cell
response. During the chronic state of HCV infection virus-specific T cells have a low frequency and
a reduced responsiveness. Based on this, a therapeutic vaccine increasing the frequency of specific
T cells is a promising alternative for the treatment of chronic HCV infection. We improved an existing
vaccine platform based on immunopotentiating reconstituted influenza virosomes (IRIVs) for efficient
delivery of peptide epitopes to the MHC class I antigen presentation pathway. IRIVs are
proteoliposomes composed of phospholipids and influenza surface glycoproteins. Due to their
fusogenic activity, IRIVs are able to deliver encapsulated macromolecules, e.g. peptides to
immunocompetent cells. We developed a novel method based on chimeric virosomes [chimeric
immunopotentiating reconstituted influenza virosomes (CIRIVs)] combining the high peptide-
encapsulation capacity of liposomes and the fusion activity of virosomes. This new approach resulted
in a 30-fold increase of the amount of incorporated soluble peptide compared with current preparation
methods. To study the immunogenicity of chimeric virosomes HLA-A2.1 transgenic mice were
immunized with CIRIVs containing the HCV Core132 peptide. Core132-CIRIVs efficiently induced
specific cytotoxic and IFNc-producing T cells already with low peptide doses. Vaccine formulations,
which include combinations of different HCV-derived CTL epitopes could be used to induce not only
a strong but also a multi-specific CTL response, making them potential candidates for therapeutic and
maybe prophylactic T cell vaccines in humans.
Introduction
Immunopotentiating reconstituted influenza virosomes (IRIVs)
have been developed to obtain a potent and well-tolerated
adjuvant for vaccines, already registered for use in humans
(1–8). IRIVs are spherical, unilamellar vesicles with a mean
diameter of ~150 nm. Their base is a liposome comprised of
phosphatidylcholine (PC), phosphatidylethanolamine (PE)
and lipids derived from the influenza virus. Phospholipids
are virtually non-immunogenic and have enjoyed a long history
of use in human pharmaceutical preparations. The haemag-
glutinin (HA) and trace quantities of viral neuraminidase and
phospholipids from influenza virus are intercalated within the
phospholipid bilayer, whereby the presence of HA is neces-
sary to enhance the immunopotentiating effect to antigens
associated with IRIVs (9). The influenza HA plays a key role in
the mode of action of the IRIVs. HA is a trimeric integral
membrane protein (Mr 220 000) comprised of an ectodomain
of identical subunits, each of which contain two polypeptides,
HA1 and HA2, linked by a disulphide bond (10). The two
polypeptides arise from a proteolytic cleavage event and are
essential for fusion activity of the virus with the endosomal
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membrane (11–13). HA1 has a high affinity for sialic acid,
which is present at relatively high concentrations on the
surface of antigen-presenting cells (APCs; e.g. macrophages,
dendritic cells). Like influenza virus IRIVs bind to sialic acid
residues on the cell surface and the entry of influenza
virosomes into cells occurs through receptor-mediated endo-
cytosis (14). At the low pH of the host cell endosome (pH ~5),
a conformational change occurs in the HA which is a pre-
requisite for fusion to occur. The HA2 subunit of HA then
mediates the fusion of virosomal and endosomal membranes.
As a result of this fusion the contents of the virosome are
released into the cytosol. Virosomes, therefore, are an elegant
carrier system for the delivery of macromolecules like antigenic
peptides, nucleic acids and others into the cell cytoplasm.
Synthetic peptide-based vaccines, which are designed to
stimulate CD8+ cytotoxic Tcells, are an attractive approach to
the treatment or prevention of infectious diseases and
malignant disorders. One major drawback of such peptide
vaccines is the rapid degradation of the peptide by proteases
(15). However, macromolecules encapsulated into virosomes
are protected from enzymatic degradation (16).
Upon endosomal fusion of the virosome containing cytotoxic
T cell (CTL) epitopes within the APC, the T cell epitopes are
released into the cytoplasm and directed into the MHC class I
antigen presentation pathway thereby leading to the induction
of CD8+ T cells. It has been shown in vitro that virosomes
containing a synthetic peptide are able to deliver the peptide
antigen to the MHC class I presentation pathway, stimulating
specific CTLs as well as rendering target cells susceptible to
antigen-specific CTL-mediated lysis (17). In order to induce
a CTL response, not only CTL epitopes have to be delivered
but also T helper epitopes. These epitopes play a critical role
in the induction of MHC class I-restricted CTL (18–21). The
virosomal carrier is also able to trigger a T helper response
since T helper epitopes are located on the influenza HA, the
major component of IRIVs. It has been demonstrated that
a synthetic peptide enclosed in virosomes is able to induce
a CTL immune response in mice (22). In addition, the use of
virosomes avoids the induction of tolerance, which has been
observed under certain conditions after immunizing mice
intra-peritoneally with soluble peptides (23).
Hepatitis C virus (HCV) is a major cause of chronic liver
diseases, such as cirrhosis and liver cancer. About 3% of the
world’s population are infectedwithHCVand~70–80%of newly
infected patients progress to chronic infection (24). Anti-viral
drugs such as IFNa/pegylated IFNa, alone or in combination
with ribavirin, are effective in up to 80% of patients (25, 26) but
many patients do not tolerate combination therapy (24). As for
many other viral infections, vaccination might be an effective
tool to control disease and therefore, it is desirable to develop
a vaccine for the treatment of chronic infection as well as to
prevent de novo infection. Recent evidence indicates that the
cellular immune response is responsible for viral clearance in
HCV-infected individuals. In particular, CTL may be a major
defence mechanism in HCV infection (27–30). The ability to
inducecytotoxic and IFNc-producingTcells is considered tobe
an important feature of a candidate HCV vaccine. Since the
core protein is the best-conserved structural protein in the HCV
genome (31), we used the HCVCore132 epitope (DLMGYIPLV,
aa 132–140) (32) as a model antigen.
One of the problems in current virosome technology is the
lack ofmethods for the efficient entrapment of peptides or other
molecules. For the induction of a good antibody immune
response (B cell immune response), the antigens must be
cross-linked to the virosome surface or integrated into the
virosome bilayer via a lipid anchor. With the widely used
detergent-removal procedure (4), efficient loading can be
achieved for such antigens (33). In contrast, for CTL epitopes,
which need to be encapsulated into virosomes, <1% of the
aqueous phase can be entrapped in the virosome particle with
the detergent-removal method and a given lipid concentration
of 1 mM and an assumed virosome diameter of ~150 nm.
Therefore, this is a rather inefficient and expensive method for
the delivery of T cell antigens in vivo. On the other hand, high
encapsulation efficiencies can be achieved by the freeze/thaw
technique used to prepare pure lipid vesicles (34). However,
liposomes lack the specific targeting to sialic acid residues on
the surface of APCs and the adjuvant effect of the HA observed
with virosomes. As a consequence, a method was developed
that combines the positive properties of virosomes and
liposomes with the result of a substantially increased entrap-
ment of peptides or other molecules within functional viro-
somes. IRIVs prepared with this novel method induce a strong
and dose-dependent CTL response against the peptide used.
Methods
Reagents and peptides
Octaethyleneglycol-mono-(n-dodecyl)ether (OEG, C12E8),
1,2-dipalmitoyl-sn-glycero-3-phospho-rac-(1-glycerol) (PG),
acetonitrile, triethylammonium phosphate (TEAP) solution,
Streptomycin, HEPES, penicillin and RPMI medium were
purchased from Fluka Chemie GmbH and Sigma (Buchs,
Switzerland), respectively. FCS was purchased from GIBCO
BRL (Basel, Switzerland). IL-2 was obtained from EuroCetus
B.V. (Amsterdam, The Netherlands). Egg PC was obtained
from Lipoid (Cham, Switzerland). PE was obtained from
R. Berchtold (Biochemical Laboratory, University of Bern,
Switzerland). SM2 Bio-Beads were from Bio-Rad Laboratories
(Glattbrugg, Switzerland). N-(4,4-difluoro-5,7-diphenyl-4-bora-
3a,4a-diaza-s-indacene-3-propionyl)-1,2-dihexadecanoyl-sn-
glycero-3-phosphoethanolamine (Bodipy 530/550-DHPE),
Lissamine rhodamine B 1,2-dihexadecanoyl-sn-glycero-3-phos-
phoethanolamine triethylammonium salt (N-Rh-DHPE) and
biotin-DHPE (N-(biotinoyl)-1,2-dihexadecanoyl-sn-glycero-3-
phosphoethanolamine, triethylammonium salt) were from
Molecular Probes Europe (Leiden, The Netherlands). Se-
phadex G50 coarse was obtained from Amersham Bio-
sciences (Otelfingen, Switzerland). Dynabeads MyOneTM
Streptavidin (10 mg ml1) were purchased from Dynal
Biotech (Hamburg, Germany).
The HLA-A2.1-binding HCV peptides Core132 (DLMGYIPLV,
aa 132–140) (32) and Core35 (YLLPRRGPRL, aa 35–44) (32)
were obtained from Bachem AG (Bubendorf, Switzerland).
Mice
Immunization experiments were performed in HHD mice
transgenic for HLA-A2.1 (A0201) monochain histocompatibility
class I molecule and deficient for both H-2Db and murine
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b2-microglobulin (35). Mice were housed in appropriate
animal care facilities and handled according to international
guidelines.
Viruses
Influenza viruses of the X-31 strain and the A/Sing (A/
Singapore/6/86) strain, propagated in the allantoic cavity of
embryonated eggs (36), were obtained from Berna Biotech
AG (Bern, Switzerland) and purified as described previously
(37). The HA : phospholipid ratio was determined by phos-
pholipid determination following the method of Bo¨ttcher (38)
and HA quantification after SDS-PAGE with the Coomassie-
extraction method following the method of Ball (39).
Preparation of chimeric immunopotentiating reconstituted
influenza virosomes
Chimeric virosomes with HA from the X-31 and the A/Sing
Influenza strain, respectively, were prepared by the method
described previously (3, 40). Briefly, 32 mg egg PC and 8 mg
PE were dissolved in 2 ml of PBS, 100 mM OEG (OEG-PBS).
Four microgramsHA of each influenza virus was centrifuged at
100 0003 g for 1 h at 4C and the pellet was dissolved in 2 ml
of OEG-PBS. The detergent-solubilized phospholipids and
viruses were mixed and sonicated for 1 min. This mixture was
centrifuged at 100 0003 g for 1 h at 20C and the supernatant
was sterile filtered (0.22 lm). Virosomes were then formed by
detergent removal using 180 mg of wet SM2 Bio-Beads for 1 h
at room temperature with shaking and three times for 30 min
with 90 mg of SM2 Bio-Beads each.
Preparation of liposomes with encapsulated peptide
A total of 36.4 lmol (28 mg) PC and 15.6 lmol (11 mg) PG
(molar ratio 70 : 30) were dissolved in methanol : chloroform
(2 : 1). The solvent was removed by a rotary evaporator
(Rotavapor R-205, Bu¨chi Labortechnik, Switzerland) at 40C at
a gradual vacuum of 30–10 kPa. The dried lipid film was
hydrated with 350 ll PBS containing 2–3.5 mg Core132
peptide to be encapsulated. Before extrusion, the volume was
adjusted to 500 ll with PBS. The liposome dispersion was
extruded 10 times through polycarbonate membranes (Nu-
cleopore Track-Etch membrane, 0.2 lm; Whatman, Kent, UK)
with a 1.5-ml Lipex Extruder (Northern Lipids, Vancouver,
Canada). Size determination of extruded liposomes was done
by light scattering using a Zetasizer 1000HS instrument
(Malvern Instruments, Worcestershire, UK).
Preparation of Core132-chimeric immunopotentiating
reconstituted influenza virosomes
Chimeric immunopotentiating reconstituted influenza viro-
somes (CIRIVs; 600 ll in PBS, ~6 mg phospholipid) were
incubated with 200 ll (~15 mg phospholipid) of PC/PG-
extruded liposomes (0.2 lm diameter) containing the Core132
peptide at 10C in PBS under constant stirring. To trigger
fusion the pH was adjusted to 4.5 with 15 ll of 1 M HCl. After
incubation for 30 min, the mixture was neutralized with 15 ll of
1 M NaOH and fusion products were extruded 10 times
through polycarbonate membranes (Nucleopore Track-Etch
membrane, 0.2 lm) with a 1.5-ml Lipex Extruder (Northern
Lipids).
Core132 peptide quantification
Peptide quantification was done by HPLC on a A¨kta Explorer
10 (Amersham Biosciences) using a CC 125/4.6 Nucleosil
100-5 C8 reversed-phase column by HPLC (RP-HPLC;
Macherey-Nagel, Oensingen, Switzerland). The following
eluents were used: buffer A, 10 mM TEAP in H2O; buffer B,
100% acetonitrile; HPLC program: flow rate 1.3 ml min1;
buffer and column temperature 25C; buffer starting concen-
tration: 25% B; 0–7 min: increase of buffer B to 38%; 7–12.4
min: increase of buffer B to 100%; 12.4–17 min: 100% buffer B.
For quantification of encapsulated peptide, a fraction (5–30 ll)
of liposomes or virosomes, respectively, were loaded on
freshly prepared, PBS-equilibrated 1 ml Sephadex G50
Coarse gel-filtration spin columns. Vesicles with encapsulated
peptide only were obtained after centrifugation of the spin
column at 3003 g for 2 min, as the non-encapsulated peptide
was retarded in the column. For spiking experiments, 0.5 mg
of peptide was added before purification to 30 ll of empty
liposomes or to 30ll of inactivated A/sing Influenza virus.
Fluorescence resonance energy transfer assay
For in vitro fusion measurements by fluorescence resonance
energy transfer (FRET) (41, 42), the following assay was de-
veloped: 0.75 mol% of Bodipy 530/550-DHPE and 0.25 mol%
of N-Rh-DHPE were incorporated into liposomes consisting of
PC : PG (70 : 30). Fluorescence measurements were carried
out at discrete temperatures between 4 and 42C in 5 mM
sodium phosphate buffer pH 7.5, 100 mM NaCl, in a final
volume of 0.8 ml in 2.5 ml poly(methyl methacrylate) (PMMA)
micro-cuvettes (VWR, Dietikon, Switzerland) under continuous
stirring. Typically, 1 ll of labelled liposomes (0.3 nmol
phospholipid) was mixed with 5–20 ll of virosomes (0.1–0.4
nmol phospholipid) and fusion was triggered by the addition of
3.75–7 ll of 1 M HCl, resulting in a pH of 4.5. The increase in
fluorescence was recorded every 5 s at excitation and
emission wavelengths of 538 and 558 nm, respectively, with
an excitation slit of 2.5 nm and an emission slit of 15.0 nm.
Measurements were carried out with an LS 55 Luminescence
spectrometer (Perkin Elmer Instruments, Schwerzenbach,
Switzerland) equipped with a thermostated cuvette holder
and a magnetic stirring device. The maximal fluorescence at
infinite probe dilution was reached after addition of Triton
X-100 (0.5% v/v final concentration). For calibration of the
fluorescence scale the initial residual fluorescence of the
liposomes was set to zero and the fluorescence at infinite
probe dilution to 100% (maximal fluorescence).
Affinity precipitation of Core132-CIRIVBio
Chimeric virosomes with HA from the X-31 and the A/Sing
Influenza strain were prepared as described in Preparation of
Chimeric Immunopotentiating Reconstituted Influenza Viro-
somes with addition of 4 mg biotin-DHPE to the phospholipid
mixture (CIRIVBio with 1 mg ml
1 biotin-DHPE). Core132-
CIRIVBio were prepared as described in Preparation of
Core132-Chimeric Immunopotentiating Reconstituted Influ-
enza Virosomes with CIRIVBio instead of regular CIRIVs. For
affinity precipitation of Core132-CIRIVBio, 5 ll of Core132-
CIRIVBio was added to buffer A (50 mM sodium phosphate,
0.1 M NaCl, pH 7.5) to a final volume of 200 ll. As controls,
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Core132-CIRIVBio were supplemented with Triton X-100 to
0.5 % (v/v), or Core132-liposomes (equal amount of peptide
as Core132-CIRIVBio) were mixed with 5 ll of empty CIRIVBio,
in a volume of 200 ll. Hundred microlitres of MyOne
Streptavidin paramagnetic beads was washed twice in buffer
A and incubated with the sample mixtures at 4C for 1.5 h with
continuous shaking. The precipitate was washed twice in
buffer A and re-suspended in 25 ll OEG-PBS. After incubation
at 4C for 5 min, the beads were removed and the supernatant
was analysed by RP-HPLC as described in Core132 Peptide
Quantification.
Immunization and cytotoxicity assay
Where indicated HLA-A2.1 transgenic mice were immunized
intramuscularly with inactivated Influenza A/Sing (1 lg HA per
dose) 3 weeks prior to immunization with vaccine formulations.
Mice were immunized subcutaneously at the base of the tail
with 100 ll of virosome formulation, liposomes with encapsu-
lated peptide, peptide with empty virosomes, peptide in saline
solution, empty virosomes or saline solution. Mice received
two injections at a 3-week interval and the response was
analysed 2 weeks after the last injection. Spleen cells (43 106
per well) from individual immunized mice were re-stimulated
for 5 days in 24-well tissue culture plates with 2 3 106
irradiated (1500 rad) spleen cells that have been pulsed with
10 lg ml1 Core132 peptide, in complete RPMI medium con-
taining 2 mM L-glutamine, 100 U ml1 penicillin, 100 lg ml1
Streptomycin, 5 mM HEPES, 10% FCS and 5 3 105 M
2-mercaptoethanol at 37C and 5% CO2. On day 2, 5 U ml1
IL-2 was added. Specific cytolytic activity was tested in
a standard 51Cr-release assay against EL4S3Rob HHD target
cells pulsed with 10 lg ml1 of Core132 peptide or medium
control. After a 4-h incubation, 51Cr release was measured by
using a c-counter. Spontaneous and maximum release was
determined from wells containing medium alone or after lysis
with 1 N HCl, respectively. Lysis was calculated by the formula:
(release in assay spontaneous release)/(maximum release
spontaneous release) 3 100. Peptide-specific lysis was
determined as the percentage of lysis obtained in the presence
or in the absence of peptide. Spontaneous release was always
<15% of maximum release.
Enzyme-linked immunospot assay
To quantify the frequency of epitope-specific IFNc-producing
cells we used the IFNc enzyme-linked immunospot (ELISPOT)
kit from U-CyTech (Utrecht, The Netherlands). Spleen cells
(6 3 106 per well) from immunized mice were re-stimulated in
24-well tissue culture plates with 10 lg ml1 Core132 peptide
or Core35 peptide (negative control) in complete RPMI
medium containing 2 mM L-glutamine, 100 U ml1 penicillin,
100 lg ml1 Streptomycin, 5 mM HEPES, 10% FCS and 5 3
105 M 2-mercaptoethanol at 37C and 5% CO2. After
overnight stimulation 105 and 104 cells from the re-stimulation
cultures were transferred in duplicates to a pre-coated and
albumin-blocked IFNc ELISPOT plate (U-CyTech) and in-
cubated for 5 h at 37C to allow cytokine secretion. Spots were
developed following the manufacturer’s instructions and were
counted by using a microscope. The background level was
assessed in wells where effector cells were stimulated with
splenocytes pulsed with Core35 peptide. The number of
peptide-specific spots was obtained by subtracting the
background from the number of spots induced after
Core132 peptide stimulation.
Intracellular IFNc staining
Spleen cells (12 3 106) were incubated with 10 lg ml1
Core132 peptide or Core35 peptide (negative control) in
complete RPMI medium containing 2 mM L-glutamine, 100 U
ml1 penicillin, 100 lg ml1 Streptomycin, 5 mM HEPES, 5%
FCS and 5 3 105 M 2-mercaptoethanol at 37C and 5% CO2
in the presence of 5 lg ml1 Brefeldin A for 4 h. Cells were
stained with FITC-conjugated anti-CD8 antibodies, permeabil-
ized and stained with PE-conjugated anti- IFNc antibodies
using the Cytofix/Cytoperm kit following the manufacturer’s
instructions (BD Pharmingen, San Diego, CA, USA). Data were
acquired on a FACSCalibur flow cytometer and analysed with
WinMDI2.8 software. Frequency of IFNc-producing cells was
calculated as percentage of IFNc-positive and CD8-positive
cells among total CD8-positive cells. The percentage of
peptide-specific cells was obtained by subtracting the
percentage in samples stimulated with Core35 peptide from
the percentage in samples stimulated with Core132 peptide.
Results
The concept of chimeric virosomes
A method was developed that combines the positive
properties of virosomes and liposomes with the result of
a substantially increased entrapment of peptides or other
molecules within functional virosomes (Fig. 1). In a first step,
a dried lipid film of PC and phosphatidylglycerol (PG) is
prepared, and liposomes are formed by re-hydration of the
film with a small volume of a concentrated peptide solution.
The formed liposomes efficiently encapsulate the peptide, but
are multi-lamellar and heterogeneous. Unilamellar and homo-
geneous liposomes are obtained after a defined number of
cycles of extrusion through a 200-nm filter. In a second step,
IRIVs with a binary mixture of HA molecules from different
influenza virus strains are prepared (hereafter called CIRIVs).
The HA molecules of the used strains display different
temperature-dependent fusion characteristics: At pH 5 or
lower, the X-31 HA triggers fusion efficiently already at low
temperatures, whereas at the same pH, the HA from the
influenza virus strain A/Sing requires elevated temperatures
(>25C) (13, 16). Thus, CIRIVs containing the HA molecules
from both the X-31 and A/Sing virions are able to catalyse two
distinct fusion reactions at a pH ~4.5, the first one at a low
temperature (<20C) and the second one at an elevated
temperature (>25C). Finally, peptide-containing CIRIVs result
from fusion of liposomes with encapsulated peptides and
CIRIVs at a pH ~4.5 and a temperature of 10C. The fused
vesicles are re-sized to a diameter of 200 nm by extrusion.
These peptide-containing proteoliposomes are supposed, like
intact influenza virus, to be taken up by cells through receptor-
mediated endocytosis. In the acidic environment of the endo-
some, the A/Sing HA molecules are expected to trigger the
second fusion reaction between the virosomal and endosomal
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membranes, with the consequent release of the peptide into
the cytosolic compartment of the cells.
Generation of Core132-CIRIVs
CIRIVs containing Core132 peptide were prepared with this
novel procedure (Fig. 1). A concentrated peptide solution of
10 mg ml1 in PBS was used to re-hydrate the lipid film.
Determination of peptide concentrations was performed on
a RP-HPLC. To remove free peptide, Core132-CIRIVs were
purified over Sephadex G50 media with a fractionation range
of Mr 1.5 3 10
3–3 3 104 for globular molecules. Therefore,
virosomes were not fractionated, whereas peptide was
retained by the media. As a control for the efficiency of this
method, a defined amount of free Core132 peptide was added
to empty liposomes or A/Sing virus and purified over
Sephadex G50 (spiking control). No Core132 was found in
the purified liposome and virus fractions, (data not shown).
Fifty to seventy five percentage of the added Core132 peptide
was encapsulated in the formed liposomes (Table 1). After
extrusion, 30–40% of the starting material was still found inside
the homogenized Core132-liposomes. To obtain the Core132-
CIRIVs, CIRIVs and Core132-liposomes were incubated at
a pH ~4.5 at 10C for 20 min. After neutralization, the fused
chimeric vesicles were homogenized by extrusion to a diam-
eter of 200 nm. In contrast to the first extrusion step applied
on Core132-liposomes, no encapsulated peptide was lost
during the extrusion of the fused chimeric vesicles. Therefore,
30–40% of the starting amount of peptide was finally found
entrapped inside the Core132-CIRIVs. Typical concentrations
obtained for the encapsulated Core132 peptide were up to
300 lg ml1. With the conventional detergent-removal method
an entrapment efficiency <1% was obtained for the Core132
peptide, as a maximal concentration of 10 lg ml1 was
determined (data not shown). The peptide concentration
inside homogenic CIRIVs did not decrease when stored at
4C for at least 4 weeks (data not shown). The peptide inside
CIRIVs is protected against degradation by proteases in vitro
(e.g. proteinase K; data not shown).
To demonstrate the efficiency of the fusion reaction between
the Core132-liposomes and the CIRIVs, an affinity precipitation
for Core132-CIRIVs was performed. For this purpose, biotin-
DHPE was incorporated into CIRIVs (CIRIVBio) before the
fusion with Core132-liposomes. Precipitation of different
samples with and without fusion with magnetic streptavidin
beads allowed the isolation of vesicles with biotin (CIRIV before
fusion, Core132-CIRIV after fusion), whereas free peptide, and
not fused Core132-liposomes, did not precipitate. The pre-
cipitate was dissolved in OEG-PBS andCore132 peptide in the
precipitate was quantified by RP-HPLC, and compared with
the starting amount of peptide (Fig. 2). After precipitation of
fused Core132-CIRIVBio ~90% of the peptide was found in the
precipitate. The presence of free Core132 peptide did not
influence the amount of affinity-precipitated Core132-CIRIVBio,
indicating the irrelevance of the presence of free peptide on
the fusion reaction (data not shown). When fused Core132-
CIRIVBio were incubated with streptavidin beads in the
presence of detergent [0.5% (v/v) Triton X-100], no Core132
peptide was detected in the precipitate, excluding unspecific
binding of Core132 peptide to the magnetic beads. When
Core132-liposomes were mixed with empty CIRIVBio without
initiating a fusion reaction, no Core132 peptidewas detected in
the precipitate, excluding stable interactions between lipo-
somes and empty CIRIVs. However, the presence of HA in
the precipitate was demonstrated by immunoblotting with an
anti-HA antibody (data not shown). These results show that
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Fig. 1. Schematic representation of the preparation of chimeric virosomes containing the Core132 peptide with the two fusion steps. In a first
fusion step, chimeric virosomes with HA from the A/Sing and the X-31 strains were fused with homogenized liposomes of a diameter of 200 nm
containing the Core132 peptide inside the particle. Fusion takes place at a pH ~4.5 and at a temperature <20C and is mediated by the HA
derived from X-31. The resulting, neutralized fusion products were used for vaccination of mice. After receptor-mediated endocytosis, a second
fusion step triggered by the low pH within endosomes and mediated by A/Sing HA takes place, releasing the Core132 peptide into the cytosol.
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under the specified conditions at least 90% of the Core132-
liposomes fused with CIRIVs.
Core132-CIRIVs are fusogenic
Tomonitor the pHand temperature-dependent fusion activity of
chimeric virosomes with liposomes in vitro, a FRET assay was
used (41). This assaymakesuse of two fluorophores, an energy
donor and an energy acceptor, both integrated in the
membrane of the liposomes. The fluorescence signal of
the energy donor is recorded continuously. Upon fusion of the
labelled liposomeswith unlabeled virosomes or influenza virus,
the two fluorophores move apart and the fluorescence emitted
by the donor increases. In this study, Bodipy 530/550-PE was
used as the donor and rhodamine–PE as the acceptor. The
fusion activity of Core132-CIRIVs was compared with that of
CIRIVs and IRIVs (A/Sing) as well as with that of A/Sing and
X-31 virus (Fig. 3). As targetmembranes, unilamellar liposomes
prepared of PC : PG (70 : 30) and the two fluorophores (donor :
acceptor, 0.75 : 0.25)were used (0.3 nmol of phospholipid) and
mixed with virosomes or virus (~0.4 nmol of phospholipid),
respectively, in a buffer at neutral pH and pre-incubated at the
defined temperature (37 or 10C). This fluorescence signal
constituted the baseline and was set to 0% fluorescence. The
fusion process was initiated by addition of HCl to reach a pH of
~4.5, and stopped by the addition of the detergent Triton X-100
to 0.5% (v/v). The latter fluorescence value corresponding to
infinite probe dilution was set to 100% fluorescence. As
expected, A/Sing virus could fuse to liposomes at 37C but
not at 10C (Fig. 3A and G). IRIVs with A/Sing HA showed the
same properties (Fig. 3B and H), whereas X-31 virus showed
fusion activity at both temperatures (Fig. 3C and I). IRIVs with
X-31 HA had the same properties as X-31 virus (data not
shown). The CIRIVs with A/Sing HA and X-31 HA consequently
could fuse both at 37 and at 10C (Fig. 3D and J). In contrast,
Core132-CIRIVs were fusogenic at 37C, but could no longer
fuse at 10C, indicating that the A/Sing HA remained functional
during the first fusion step at 10C (Fig. 3E and K). As a control,
no fusion was observed with Core132-CIRIVs when buffer
instead of HCl was added (pH 7.5; Fig. 3F and L), or when
unlabeled liposomes or inactivated virosomes were used (data
not shown). Homogenic Core132-CIRIVs remained fusogenic
for at least 4 weeks when stored at 4C (data not shown).
CD8+ T cell response induced by chimeric virosomes with
encapsulated peptide
To study the immunogenicity of the CIRIVs HLA-A2 transgenic
mice were immunized twice with CIRIV formulations containing
various concentrations of the Core132 peptide (2, 5.5 and
10 lg per dose) or empty CIRIVs or PBS as negative controls.
Two weeks after the last immunization spleen cells of individual
mice were isolated and re-stimulated in vitro with peptide.
After 5 days of in vitro stimulation, the CTL response for
Core132 peptide was investigated by 51Cr-release assay
using HHD-transfected EL4 cells as target cells. In two
independent experiments all the Core132 containing CIRIV
formulations induced a strong CTL response in all of the
immunized mice (Fig. 4A and B). The strength of the induced
response was dose dependent with the highest dose giving
the highest specific lysis of ~47% lysis at an E : T ratio of 33 : 1.
Neither in naive mice nor in mice immunized with empty
CIRIVs a substantial lysis of the target cells could be detected.
In addition, IFNc release was chosen as another indicator of
T cell response induced by Core132-CIRIV immunization.
IFNc release was quantified by ELISPOT assay (Fig. 5). The
numbers of IFNc-producing cells correlated well with the
peptide-specific cytotoxicity with higher numbers induced by
higher amounts of Core132 peptide in the CIRIV formulations.
In control experiments with three mice per group using the
same immunization schedule and the same methods for
analysis neither large unilamellar vesicles (LUVs) with encap-
sulated peptide (20 lg per dose), nor peptide with empty
virosomes (20 lg per dose) nor peptide in saline solution
(20 lg per dose) induced a detectable immune response in
the 51Cr-release assay and the ELISPOT assay (data not
shown).
To get a better idea about the frequency of specific T cells
in the CD8+ population, another set of experiments were
performed using staining for intracellular IFNc. In addition, we
wanted to test whether pre-existing immunity to influenza,
which better reflects the situation in humans would affect the
induction of HCV Core132-specific CTL. Therefore, naive and
influenza immune mice were vaccinated and boosted 3 weeks
later with the same Core132-CIRIV formulations or Core132-
LUV and the frequency of specific IFNc-producing cells was
determined in the CD8+ population with flow cytometry.
Table 1. Encapsulation efficiency for Core132
Particle type Particle
diameter (lm)
Encapsulated
peptidea(%)
Liposomes up to 1.2 50–75
Homogenized liposomes 0.2 30–40
Fused chimeric virosomes 0.4–0.8 30–40
Homogenized virosomes 0.2 30–40
aIn percentage of starting material. Data represent the range
determined from at least five separate preparations. 0 20 40 60 80 100
Core132 [% of input]
Precipitate
Core132-CIRIV
Precipitate
Core132-CIRIV & Triton X-100
Precipitate
CIRIV & Core132-Liposomes
Control
Core132-CIRIV
Fig. 2. Affinity precipitation of Core132-CIRIVBio was carried out as
described in Methods. Core132-CIRIVBio were mixed with streptavidin
magnetic beads and the precipitate was solubilized in OEG-PBS and
analysed by RP-HPLC. In a first control experiment, Core132-CIRIVBio
were incubated with streptavidin magnetic beads in the presence of
0.5% (v/v) Triton X-100. In a second control experiment, Core132-
liposomes were mixed with empty CIRIVBio and incubated with
streptavidin magnetic beads. An equal amount of Core132-CIRIVBio
starting material was purified over Sephadex G50 and analysed by
RP-HPLC. A representative result out of three separate experiments is
shown.
700 Novel chimeric influenza virosomes for CTL induction
Compared with the Core132-LUV-vaccinated mice (negative
control) in most of the Core132-CIRIV-vaccinated mice an
increased frequency of peptide-specific CD8+ Tcells could be
detected with a maximal frequency of 2.6% (Fig. 6). In addition
pre-existing immunity to influenza had no effect on the
frequency of peptide-specific CD8+ T cells.
Discussion
The experiments described represent an effort to develop an
improved virosome-based carrier system for the delivery of
macromolecules (e.g. peptides) into cells, especially used as
therapeutic vaccines. Since IRIVs are already registered for
human use (4) and because of their safety profile and their
rapid cellular uptake HA-virosomes represent a promising
system. A further advantage of HA-virosomes is their potential
targeting to specific cells or tissues by co-reconstituting
receptors or antibodies (43) within the virosomal membrane.
For this purpose a high concentration of the encapsulated
macromolecules is of great importance. In addition, HA-
virosomes have been shown to work as an excellent adjuvant
in humans (44), a characteristic that is of interest for the use
of HA-virosomes in vaccination. We have described a new
methodology to improve the encapsulation efficiency by using
CIRIVs. CIRIVs combine the advantages of liposomes and
virosomes, namely the high encapsulation efficiency of
liposomes, the receptor-mediated endocytosis and the mem-
brane fusion properties of virosomes as well as the adjuvant
37°C 10°C
IRIV (A/Sing)
C X-31 virus CIRIV (X-31 / A/Sing)
E Core132-CIRIV Core132-CIRIV pH 7.5
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I X-31 virus CIRIV (X-31 / A/Sing)
K Core132-CIRIV Core132-CIRIV pH 7.5
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Fig. 3. Fusion activity of Core132-CIRIVs and its precursors. FRET measurements were carried out as outlined in Methods at 37C (A–F) and 10C
(G–L), respectively, with the following samples: A/Sing Influenza virus (A and G), A/Sing virosomes (B and H), X-31 Influenza virus (C and I),
chimeric A/Sing/X-31 virosomes before fusion with liposomes (D and J), Core132-CIRIVs (E and K) and Core132-CIRIVs without pH change (F and
L). Labelled liposomes (0.3 nmol of phospholipid) weremixed with virosomes or virus (~0.4 nmol of phospholipid). Closed arrowheads indicate the
addition of protons (pH change to ~4.5) and open arrowheads indicate the addition of Triton X-100 to 0.5% (v/v). For calibration of the fluorescence
scale the initial residual fluorescence of the liposomes was set to zero and the fluorescence at infinite probe dilution to 100% (maximal
fluorescence). Please note that for the measurements E, F, K and L, a higher amount (53) of virosomes was used.
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effect of virosomes. As a model antigen peptide, we showed
that 30–40% of the supplied HCV Core132 nonapeptide could
be incorporated into functional virosomes, whereas with the
conventional detergent-removal method, entrapment efficien-
cies <1% were observed. The prepared proteoliposomes
were found to undergo efficient fusion with model membranes
at low pH and elevated temperatures. In contrast to previous
reports with other virosomes (45, 46), no leakage was
observed with Core132-CIRIVs during the fusion process, in
agreement with the situation for alphaviruses (47).
The present method has also been used for the incorpor-
ation of other peptides with similar results. Lower entrapment
efficiencies were generally obtained with hydrophobic pep-
tides (M. Amacker, unpublished results). Furthermore, CIRIVs
can also be used for different applications. Virosomes are, for
example, a suitable carrier system for DNA and RNA since
these fusogenic particles mimic a virus. The genetic material is
enclosed in the virosome and is therefore protected from
DNases and RNases. Virosomes could also serve as a drug
delivery system to the cytosol. Using mAbs to tumour-
associated antigens, virosomes could be targeted to cancer
cells and therefore allow specific immunotherapy (48).
CTL epitope-based vaccine approaches offer a number of
potential advantages (49). These include safety aspects, the
possibility of inducing an immune response directed only
against the relevant epitope and the ability to modify an
epitope sequence to enhance the potency of the vaccine (50).
In addition, they can be easily produced by peptide synthesis
in large amounts at modest cost. Therefore, based on
a suitable carrier, synthetic peptide epitopes are a very
attractive approach for vaccine development.
As we have shown so far, we could efficiently encapsulate
a peptide CTL epitope into CIRIVs. To study the efficiency of
those CIRIVs in inducing a CTL response we used a model
based on transgenic mice expressing human HLA-A2.1. The
use of this model not only shows the immunogenicity of our
newly developed CIRIVs but also may serve as an excellent
tool for screening candidate epitopes for human vaccines in
the future.
Our data indicate that CIRIVs containing Core132 peptide
efficiently induce specific cytotoxic and IFNc-producing Tcells
in HLA-A2.1 transgenic mice. Those responses were dose
dependent and even the lowest dose of 2 lg peptide per
injection induced a detectable CTL response.
As a very important point we were able to show that pre-
existing immunity to influenza virus, reflecting the situation in
humans, did not affect the induction of IFNc-producing CD8+
T cells by CIRIV. On the contrary it can be speculated that
influenza-specific CD4+ T cells could provide help to rise
a CTL response directed against the peptide encapsulated in
the virosome. Such a phenomenon has been observed in vitro
with human PBMCs where virosomes activated CD4+/
CD45RO+ T cells and induced a cytokine profile consistent
with Th1 stimulation (51). Alternatively, the lack of adjuvancy
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Fig. 4. Cytotoxic T cell responses in Core132-CIRIV-immunized HHD
mice. In two independent experiments (A) and (B) HHD mice (2–3
mice per group) were immunized twice subcutaneously at a 3-week
interval with empty IRIVs or Core132-CIRIVs. Spleen cells were
isolated 2 weeks after the second immunization. After 5 days of in vitro
re-stimulation with Core132 peptide, the stimulated spleen cells were
used as effector cells against HHD-transfected EL4 as target cells in
a Cr-release assay with an E : T ratio starting at 33 : 1. (A) Mice were
immunized with empty IRIVs (open circles), or CIRIVs containing 2 lg
(closed circles) or 5.5 lg (triangles) Core132 per dose. (B) Mice were
naive (open circles) or immunized with CIRIVs containing 5.5 lg
(triangles) or 10 lg (squares) Core132 per dose. Results show peptide
mean specific lysis (lysis of target cells with peptide—lysis of target
cells without peptide) of 2–3 individual mice 6 standard deviation.
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Fig. 5. IFNc-producing cells in Core132-CIRIV-immunized HHD mice.
HHD mice (2–3 mice per group) were immunized twice subcutane-
ously at a 3-week interval with Core132-CIRIVs. Spleen cells were
isolated 2 weeks after the second immunization. The spleen cells were
isolated and stimulated overnight with Core132 peptide or Core35
peptide (negative control). The number of IFNc-producing T cells was
determined in an ELISPOT assay as described in Methods. Specific
IFNc-producing cells were determined by counting the number of
spots in the presence of Core132 peptideminus the number of spots in
the presence of Core35 peptide. Shown are the mean values as
derived from 2–3 individual mice 6 standard deviation.
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found in these experiments may also reflect a limitation of the
transgenic mouse model.
These data provide evidence that peptide bearing CIRIVs
remain fusogenic and are effective at inducing specific,
cytotoxic and IFNc-producing T cells in HLA-A2.1 transgenic
mice. Therefore, such vaccine formulations including combin-
ations of different CTL epitopes could be used to induce not
only a strong but also a multi-specific CTL response, making
them potential candidates for prophylactic and/or therapeutic
vaccines in humans against HCV and other targets, especially
as virosome formulation are already accepted for use in
humans.
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Abbreviations
APC antigen-presenting cell
Bodipy 530/
550-DHPE
N-(4,4-difluoro-5,7-diphenyl-4-bora-3a,4a-diaza-s-
indacene-3-propionyl)-1,2-dihexadecanoyl-sn-glycero-
3-phosphoethanolamine
CIRIV chimeric immunopotentiating reconstituted
influenza virosome
ELISPOT enzyme-linked immunospot
FRET fluorescence resonance energy transfer
HA haemagglutinin
HCV hepatitis C virus
IRIV immunopotentiating reconstituted influenza
virosome
LUV large unilamellar vesicles
N-Rh-DHPE Lissamine rhodamine B 1,2-dihexadecanoyl-
sn-glycero-3-phosphoethanolamine
triethylammonium salt
OEG octaethyleneglycol-mono-(n-dodecyl)ether
PC phosphatidylcholine
PE phosphatidylethanolamine
PG 1,2-dipalmitoyl-sn-glycero-3-phospho-rac-
(1-glycerol)
RP-HPLC reversed-phase column by HPLC
TEAP triethylammonium phosphate
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